13F Holdings
中文EN

TKNO Alpha Teknova, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1850902 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.4%
TTM net income YoY12.3%
TTM EPS YoY9.1%
Revenue 3-yr CAGR7.8%
Net income 3-yr CAGR—

Margins

Gross margin36.4%
Operating margin-32.7%
Net margin-34.8%
FCF margin-13.9%
EBITDA margin-20.1%

Returns

ROE-24.1%
ROA-15.8%
ROIC (approx.)-15.9%
Asset turnover0.45x

Leverage & solvency

Liabilities / assets36.9%
Debt / equity0.22x
Current ratio3.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$40.52M$37.74M$36.68M$41.42M$36.89M
Cost of revenue$27.08M$30.51M$26.39M$23.94M$19.27M
Gross profit$13.44M$7.23M$10.30M$17.48M$17.62M
R&D expense$2.20M$2.76M$5.57M$7.74M$4.31M
SG&A expense$20.32M$23.15M$25.45M$28.30M$20.39M
Operating income-$16.98M-$26.15M-$35.56M-$49.66M-$12.01M
Pretax income-$17.20M-$26.83M-$37.08M-$49.39M-$12.64M
Income tax$58,000-$88,000-$298,000-$1.92M-$2.83M
Net income-$17.26M-$26.75M-$36.78M-$47.47M-$9.80M
EBITDA-$10.63M-$19.57M-$29.90M-$45.16M-$9.12M
EPS (basic)-0.32-0.57-1.16-1.69-0.61
EPS (diluted)-0.32-0.57-1.16-1.69-0.61
Weighted avg. shares (diluted)53.48M46.75M31.82M28.08M16.09M
Banking
Net interest income-$710,000-$687,000-$833,000$213,000-$589,000
Balance sheet
Cash & equivalents$5.91M$3.71M$28.48M$42.24M$87.52M
Short-term investments$15.43M$26.69M$0—$0
Receivables$4.62M$4.31M$3.95M$4.26M$4.67M
Inventory$7.05M$6.80M$11.59M$12.25M$5.39M
Current assets$34.51M$42.78M$45.66M$61.14M$101.20M
PP&E, net$41.73M$45.75M$50.36M$51.58M$29.81M
Goodwill———$0$16.61M
Intangibles$11.94M$13.09M$14.24M$17.56M$18.70M
Total assets$103.58M$118.77M$128.59M$152.26M$166.51M
Current liabilities$7.54M$11.21M$8.88M$10.88M$7.74M
Short-term debt$0$4.04M$0$0—
Long-term debt$13.12M$9.44M$13.25M$21.98M$11.87M
Total debt$13.12M$13.49M$13.25M$21.98M$11.87M
Total liabilities$34.81M$36.38M$38.55M$52.38M$23.31M
Shareholders' equity$68.78M$82.39M$90.04M$99.89M$143.20M
Net debt$7.21M$9.78M-$15.23M-$20.26M-$75.65M
Shares outstanding53.56M53.41M40.79M28.18M28.01M
Cash flow statement
Operating cash flow-$8.65M-$12.39M-$18.81M-$27.40M-$9.07M
Capital expenditure$1.15M$1.12M$7.93M$28.15M$19.88M
Free cash flow-$9.79M-$13.52M-$26.75M-$55.55M-$28.95M
Investing cash flow$10.70M-$27.27M-$7.74M-$28.15M-$17.52M
Financing cash flow$151,000$14.89M$12.80M$10.27M$110.79M
Depreciation & amortization$6.34M$6.58M$5.66M$4.50M$2.88M
Stock-based compensation$3.43M$3.67M$4.14M$3.71M$1.55M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.